Spinnaker Trust Sells 367 Shares of Danaher Corporation $DHR

Spinnaker Trust trimmed its holdings in shares of Danaher Corporation (NYSE:DHR) by 7.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 4,332 shares of the conglomerate’s stock after selling 367 shares during the period. Spinnaker Trust’s holdings in Danaher were worth $856,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sierra Ocean LLC raised its stake in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after buying an additional 76 shares during the last quarter. Red Tortoise LLC grew its position in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the last quarter. Ramirez Asset Management Inc. bought a new stake in Danaher during the 2nd quarter valued at about $40,000. Costello Asset Management INC purchased a new position in Danaher in the first quarter worth about $41,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of Danaher by 53.8% during the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock valued at $42,000 after buying an additional 71 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $214.97 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The business has a 50-day moving average price of $203.33 and a 200-day moving average price of $199.31. The firm has a market cap of $151.84 billion, a price-to-earnings ratio of 44.32, a price-to-earnings-growth ratio of 3.28 and a beta of 0.77.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the previous year, the firm earned $1.71 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on DHR shares. Robert W. Baird set a $247.00 price objective on shares of Danaher in a report on Wednesday, October 22nd. TD Cowen lifted their price target on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Barclays boosted their price target on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Bank of America decreased their target price on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Finally, UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.